International CRO Signs Agreement With OmniComm Systems for TrialMaster EDC
Fort Lauderdale, FL (GLOBE NEWSWIRE)- A full-service contract research organization, with clinical operations on three continents, has signed an agreement to use TrialMaster EDC from OmniComm Systems, Inc., a provider of clinical data management technology. Under the terms of the agreement, the CRO will use OmniComm’s TrialMaster for future studies, including an upcoming Phase Ib study on behalf of a sponsor based in the UK.
The CRO chose TrialMaster to complement an existing in-house EDC system and to provide additional support tools for more complex study designs. The CRO selected OmniComm because of TrialMaster’s built-in patient questionnaire capability, site experience for data collection and easy-to-use study build tools. OmniComm will provide the CRO with technology, training, study development, quality assurance and project management support.
“We are excited to have been selected as the organization’s EDC technology provider,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “To have another key CRO in Europe choose TrialMaster because of the very modern user interface and fast study build capability is very rewarding. The CRO team also appreciated the built-in ability to deploy patient questionnaires, which will be a key component for capturing data directly from patients in the initial study.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
